Oxford University, the oldest university in England, will be at the forefront of a new global center of excellence set up to carry out a £10 million dollar research program to study cannabis. The initial investment, which equates to about $12.36 million US, is being provided by the private equity company, Kingsley Capital Partners, and will be funded through its new biopharmaceutical firm Oxford Cannabinoid Technologies (OCT).
Read Full article at MedicalJane.com